- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cambridge Today
By the People, for the People
Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program for AI-Driven Cell Therapy Manufacturing
Partnership accelerates development of autonomous workflows in GMP cleanroom environments
Published on Feb. 11, 2026
Got story updates? Submit your updates here. ›
Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company, have launched an exclusive Early Adopter and Design Partner Program. Through this program, Made Scientific will serve as Streamline Bio's exclusive early adopter, design partner, and preferred CDMO partner to co-develop, integrate, and validate Streamline Bio's AI-driven robotic manufacturing platform in a GMP-ready environment.
Why it matters
This partnership aims to accelerate the development of automated workflows for cell therapy manufacturing, including new unit operations, enhanced analytics/data capture, and AI-based improvements to support scalable GMP operations. The goal is to enable more repeatable, efficient, and cost-effective cell therapy production to broaden patient access.
The details
The program will evaluate autonomous rapid CAR-T manufacturing through end-to-end automation of critical process steps, targeting cycle-time optimization, process robustness, and operational scalability. Made Scientific will integrate and validate Streamline Bio's technology within its GMP manufacturing operations in Princeton, NJ, advancing the technology in a real-world GMP setting.
- The partnership was announced on February 10, 2026.
The players
Made Scientific
A leading US-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply.
Streamline Bio
A next-generation autonomous robotics company transforming biomanufacturing with AI-driven precision robotics.
What they’re saying
“We are pleased to formalize our role as Streamline Bio's exclusive CDMO technology partner as they work to redefine cell therapy manufacturing through advanced AI-driven automation.”
— Syed T. Husain, Chairman & CEO of Made Scientific
“Streamline Bio's technology is purpose-built to deliver low-cost, versatile, and scalable automation for life science manufacturing.”
— Rodney Rietze, President & CEO of Streamline Bio
What’s next
The partnership will focus on accelerating the development of automated workflows, including new unit operations, enhanced analytics/data capture, and AI-based improvements to support scalable GMP operations for cell therapy manufacturing.
The takeaway
This exclusive partnership between Made Scientific and Streamline Bio aims to advance AI-driven robotic automation in cell therapy manufacturing, with the goal of enabling more repeatable, efficient, and cost-effective production to broaden patient access to transformative cell therapies.
